Current issues of novel risk factors for coronary disease and interventions for arrhythmias Valentin Fuster Invited Commentary Pages: v - vii
Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis Paul M. Ridker Clinical Trials Review Pages: 88 - 90
The role of C-reactive protein in cardiovascular disease risk Michelle A. AlbertPaul M. Ridker OriginalPaper Pages: 99 - 104
Lipoprotein(a) and coronary heart disease risk Santica M. MarcovinaRobert A. HegeleMarlys L. Koschinsky OriginalPaper Pages: 105 - 111
Fibrinolytic function and coronary risk Irène Juhan-VaguePierre MorangeMarie Christine Alessi OriginalPaper Pages: 119 - 124
The ablate-and-pace strategy in atrial fibrillation Peter O'Callaghan Clinical Trials Review Pages: 132 - 134
Evidence-based medicine and the implantable defibrillator Richard N. Fogoros OriginalPaper Pages: 135 - 141
Catheter-ablative techniques for the treatment of atrial fibrillation Peter G. GuerraMichael D. Lesh OriginalPaper Pages: 142 - 148
Recent advances in cardiac mapping techniques Claus SchmittGjin NdrepepaMichael Schneider OriginalPaper Pages: 149 - 156
Ablation of ventricular tachycardia in the setting of coronary artery disease Allison W. RichardsonMark E. Josephson OriginalPaper Pages: 157 - 164
Alternate energy sources for catheter ablation Paul J. WangMunther K. HomoudN. A. Mark Estes III OriginalPaper Pages: 165 - 171